Allarity Therapeutics (NASDAQ: ALLR) reported quarterly earnings per share (EPS) of $(0.21) for the second quarter ended June 30, 2026, beating the analyst consensus estimate of $(0.25) by 16 percent. While the result was better than expected, it marks a 40 percent widening of losses compared to $(0.15) per share in the corresponding period of 2025.

The company posted a net loss of $3.4 million for the quarter, up from a $2.3 million loss in Q2 2025. Allarity ended the quarter with $26.9 million in cash and restricted cash, an increase from $14.7 million as of June 30, 2025.

Financial Performance

The widening net loss was driven primarily by higher interest expense and foreign exchange losses, which offset significant reductions in operating costs. Research and development (R&D) expenses fell to $1.3 million from $2.3 million year-over-year, while general and administrative (G&A) expenses declined to $1.3 million from $1.8 million.

Total operating expenses for the quarter were $2.7 million, a sharp decrease from $4.1 million in Q2 2025. This reduction contributed to an operating loss of $2.7 million, compared to $4.1 million in the prior year period.

However, other income and expenses negatively impacted the bottom line. Interest expense surged to $719,000 from just $12,000 in the previous year quarter. Additionally, the company recorded a $104,000 foreign exchange loss, contrasting with a $1.6 million gain in Q2 2025. A $128,000 change in fair value of derivative and warrant liabilities also weighed on results.

For the six months ended June 30, 2026, the company reported a net loss of $6.2 million, compared to $5.1 million in the same period of 2025. License revenue for the first half of FY26 was $25,000, whereas no license revenue was recognized in H1 2025.

What the Numbers Show

The divergence between improving operational efficiency and worsening non-operating costs is notable. While Allarity successfully reduced its core burn rate by cutting R&D and G&A expenses by approximately 35% and 28% respectively, these savings were largely neutralized by a spike in interest expense and the reversal of foreign exchange gains. The net loss widened by roughly 47% year-over-year despite the operating loss narrowing by nearly 35%, indicating that financial charges and currency fluctuations are currently the primary drivers of profitability metrics rather than operational execution.

Operational Highlights

Beyond financial results, Allarity announced several key milestones in its drug development pipeline:

• Manufacturing Completion: The company completed its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib in July 2026, ahead of the originally planned third-quarter completion. All manufacturing payments were made during Q2 and recorded as prepaid expenses.
• Patent Grant: The USPTO granted a key U.S. patent covering the stenoparib-specific Drug Response Predictor (DRP) companion diagnostic, extending exclusivity into April 2042.
• CLIA Certification: Allarity obtained CLIA certification for its in-house laboratory in Denmark, enabling internal DRP testing for U.S. clinical trials.
• Clinical Data: At the AACR 2026 meeting, the company presented data linking higher DRP scores with enhanced overall survival in advanced ovarian cancer patients.

The company continues enrollment in its Phase 2 trials for advanced ovarian cancer under FDA Fast Track designation and for relapsed small cell lung cancer in combination with temozolomide.

Allarity Therapeutics, Inc. has secured a key U.S. patent for its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic from the United States Patent and Trademark Office (USPTO). The patent grant provides intellectual property protection for the diagnostic technology used to identify patients likely to respond to the company's drug candidate. The newly granted patent holds a term extending into April 2042, offering long-term market exclusivity for this specific diagnostic application.

The patent issuance follows the USPTO’s prior Notice of Allowance for the stenoparib DRP® companion diagnostic, which Allarity announced in April 2026. Stenoparib (2X-121) is a differentiated, dual PARP and WNT pathway inhibitor currently in Phase 2 clinical-stage development. The DRP® companion diagnostic is designed to guide the therapeutic use of stenoparib by predicting patient response, aiming to optimize clinical outcomes.

Patent Details

The following table outlines the key details regarding the intellectual property grant:

Allarity focuses on developing stenoparib as a targeted oncology treatment. The integration of the DRP® companion diagnostic is central to the company's strategy, intending to enhance the precision of the drug's application in clinical settings.